Tags

Type your tag names separated by a space and hit enter

Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk.
Am J Ind Med 2002; 42(1):29-37AJ

Abstract

BACKGROUND

As observed in tobacco-associated carcinogenesis, genetic factors such as the polymorphic metabolic/oxidative enzyme myeloperoxidase (MPO) could modulate individual susceptibility to asbestos-associated carcinogenesis.

METHODS

RFLP-PCR analysis identified the MPO genotypes in 375 Caucasian lung cancer cases and 378 matched controls. An epidemiological interview elicited detailed information regarding smoking history and occupational history and exposures.

RESULTS

Asbestos exposure was associated with a significantly elevated risk estimate (OR = 1.45; 95% CI 1.04-2.02). On stratified analysis, we found the MPO genotypes modified the effect of asbestos exposure on lung cancer risk. Specifically, G/G carriers who were exposed to asbestos had an odds ratio (OR) of 1.72 (95% CI; 1.09-2.66), while A-allele carriers (G/A + A/A) exposed to asbestos exhibited a reduced OR of 0.89 (95% CI; 0.56-1.44). The OR was further reduced to 0.73 (0.49-1.06) for A-allele carriers not exposed to asbestos. A similar trend was observed for the joint effects between the MPO genotypes and pack-years smoking. Next, all three risk factors (MPO genotypes, asbestos exposure, and smoking) were analyzed simultaneously for joint effects. Heavy smokers with the G/G genotype and a history of asbestos exposure demonstrated a statistically significant elevated risk estimate (OR = 2.19; 95% CI 1.16-4.11), while the A-allele carriers with the same exposure profile were at a lower risk for lung cancer (OR = 1.18; 95% CI 0.58-2.38). The A-allele genotypes demonstrated similar protective effects for the other three exposure profiles.

CONCLUSIONS

For a similar level of exposure to established carcinogens, individuals with the MPO A-allele genotypes appear to have a reduced risk of lung cancer.

Authors+Show Affiliations

Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77303, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12111688

Citation

Schabath, Matthew B., et al. "Association Between Asbestos Exposure, Cigarette Smoking, Myeloperoxidase (MPO) Genotypes, and Lung Cancer Risk." American Journal of Industrial Medicine, vol. 42, no. 1, 2002, pp. 29-37.
Schabath MB, Spitz MR, Delclos GL, et al. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. Am J Ind Med. 2002;42(1):29-37.
Schabath, M. B., Spitz, M. R., Delclos, G. L., Gunn, G. B., Whitehead, L. W., & Wu, X. (2002). Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. American Journal of Industrial Medicine, 42(1), pp. 29-37.
Schabath MB, et al. Association Between Asbestos Exposure, Cigarette Smoking, Myeloperoxidase (MPO) Genotypes, and Lung Cancer Risk. Am J Ind Med. 2002;42(1):29-37. PubMed PMID: 12111688.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. AU - Schabath,Matthew B, AU - Spitz,Margaret R, AU - Delclos,George L, AU - Gunn,Gary B, AU - Whitehead,Lawrence W, AU - Wu,Xifeng, PY - 2002/7/12/pubmed PY - 2002/9/13/medline PY - 2002/7/12/entrez SP - 29 EP - 37 JF - American journal of industrial medicine JO - Am. J. Ind. Med. VL - 42 IS - 1 N2 - BACKGROUND: As observed in tobacco-associated carcinogenesis, genetic factors such as the polymorphic metabolic/oxidative enzyme myeloperoxidase (MPO) could modulate individual susceptibility to asbestos-associated carcinogenesis. METHODS: RFLP-PCR analysis identified the MPO genotypes in 375 Caucasian lung cancer cases and 378 matched controls. An epidemiological interview elicited detailed information regarding smoking history and occupational history and exposures. RESULTS: Asbestos exposure was associated with a significantly elevated risk estimate (OR = 1.45; 95% CI 1.04-2.02). On stratified analysis, we found the MPO genotypes modified the effect of asbestos exposure on lung cancer risk. Specifically, G/G carriers who were exposed to asbestos had an odds ratio (OR) of 1.72 (95% CI; 1.09-2.66), while A-allele carriers (G/A + A/A) exposed to asbestos exhibited a reduced OR of 0.89 (95% CI; 0.56-1.44). The OR was further reduced to 0.73 (0.49-1.06) for A-allele carriers not exposed to asbestos. A similar trend was observed for the joint effects between the MPO genotypes and pack-years smoking. Next, all three risk factors (MPO genotypes, asbestos exposure, and smoking) were analyzed simultaneously for joint effects. Heavy smokers with the G/G genotype and a history of asbestos exposure demonstrated a statistically significant elevated risk estimate (OR = 2.19; 95% CI 1.16-4.11), while the A-allele carriers with the same exposure profile were at a lower risk for lung cancer (OR = 1.18; 95% CI 0.58-2.38). The A-allele genotypes demonstrated similar protective effects for the other three exposure profiles. CONCLUSIONS: For a similar level of exposure to established carcinogens, individuals with the MPO A-allele genotypes appear to have a reduced risk of lung cancer. SN - 0271-3586 UR - https://www.unboundmedicine.com/medline/citation/12111688/Association_between_asbestos_exposure_cigarette_smoking_myeloperoxidase__MPO__genotypes_and_lung_cancer_risk_ L2 - https://doi.org/10.1002/ajim.10084 DB - PRIME DP - Unbound Medicine ER -